Inventor · disambiguated record
Jeroen Aerssens
Also filed as: AERSSENS JEROEN · AERSSENS JEROEN MARCEL MARIA ROGER
3 granted patents·19 pending applications·10 citations·filing 2002–2021
61Inventor score
Files withGENAISSANCE PHARMACEUTICALS11JANSSEN PHARMACEUTICA NV3JANSSEN SCIENCES IRELAND UNLIMITED CO2PGXHEALTH LLC2ACAD ZIEKENHUIS LEIDEN A/U LEIDEN UNI MEDICAL CTR1
Top patents by PatentIndex Score
22 records- 0169US7250258B2CDK5 genetic markers associated with galantamine responsePGXHEALTH LLC·Filed 2004·Granted Jul 31, 2007·6 cites·26 claims
- 0265US8725418B2Data mining of SNP databases for the selection of intragenic SNPsAERTS JAN·Filed 2002·Granted May 13, 2014·4 cites·61 claims
- 0353US2022090217A1Biomarkers and uses thereof in the treatment of chronic hbv infectionJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2021·Application pending·0 cites
- 0452US2008166723A1CDK5 genetic markers associated with galantamine responsePGXHEALTH LLC·Filed 2007·Application pending·0 cites
- 0550US2023332230A1Biomarkers and uses thereof in the treatment of chronic hepatitis b infectionJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2021·Application pending·0 cites
- 0648US2005255495A1SLC5A7 genetic markers associated with age of onset of Alzheimer's diseaseGENAISSANCE PHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 0747US2006166219A1NTRK1 genetic markers associated with progression of Alzheimer's diseaseGENAISSANCE PHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 0847US2005250122A1APOA4 genetic markers associated with progression of Alzheimer's diseaseGENAISSANCE PHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 0947US2005255492A1CHRNA9 genetic markers associated with progression of Alzheimer's diseaseGENAISSANCE PHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 1047US2005260613A1LRPAP1 genetic markers associated with galantamineGENAISSANCE PHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 1147US2005250118A1EPHX2 Genetic markers associated with galantamineGENAISSANCE PHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 1247US2005250121A1NTRK2 genetic markers associated with progression of Alzheimer's diseaseGENAISSANCE PHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 1347US2005255488A1NTRK1 genetic markers associated with age of onset of Alzheimer's DiseaseGENAISSANCE PHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 1445US2010222228A1Compositions and methods for treating and diagnosing irritable bowel syndromeJANSSEN PHARMACEUTICA NV·Filed 2007·Application pending·0 cites
- 1542US2005048543A1CHRNA2 genetic markers associated with galantamine responseFiled 2004·Application pending·0 cites
- 1640US10975441B2R2R1/2 in diagnosis and therapyACAD ZIEKENHUIS LEIDEN A/U LEIDEN UNI MEDICAL CTR·Filed 2016·Granted Apr 13, 2021·0 cites·8 claims
- 1739US2009048194A1Vagal Afferent Neurons as Targets for TreatmentJANSSEN PHARMACEUTICA NV·Filed 2006·Application pending·0 cites
- 1837US2006154265A1LDLR genetic markers associated with age of onset of Alzheimer's DiseaseGENAISSANCE PHARMACEUTICALS·Filed 2005·Application pending·0 cites
- 1937US2005277129A1APOE genetic markers associated with age of onset of Alzheimer's diseaseGENAISSANCE PHARMACEUTICALS·Filed 2005·Application pending·0 cites
- 2037US2005255498A1APOC1 genetic markers associated with age of onset of Alzheimer's DiseaseGENAISSANCE PHARMACEUTICALS·Filed 2005·Application pending·0 cites
- 2135US2014068794A1R2R1/2 In Diagnosis and TherapyJANSSEN PHARMACEUTICA NV·Filed 2013·Application pending·0 cites
- 2235US2012252695A1Predictive Value of IL28B Gene Polymorphism Combined with Pretreatment Serum IP-10 Quantification for Response to Peginterferon and Ribavirin Is Enhanced in Comparison with any of these Biomarkers aloneAERSSENS JEROEN·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →